Nadeem Vaidya, MD
Retina Specialist · Irvine, CANPI 1578616520
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alimera Sciences, Inc. at 41.8% of the total. Reporting peaked in 2019 at $8,086 and has fallen 95.4% since, to $369 in 2025.
Across 102 payments — averaging $176.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$8K
- AbbVie$4K
- Optos, Inc.$3K
- Genentech USA, Inc.$517
- Regeneron Healthcare Solutions, Inc.$440
- Apellis Pharmaceuticals, Inc.$392
- plus $2K from 14 others
What the payments were for
- Consulting fees$4,31324%
- Speaking & faculty fees$10,20057%
- Food & beverage$3,41119%
- Education$400%
- Gifts$390%
- Entertainment$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 13 | $7,540 |
| AbbVie(2 entities) | 7 | $4,429 |
| Optos, Inc. | 3 | $3,017 |
| Genentech USA, Inc. | 11 | $517 |
| Regeneron Healthcare Solutions, Inc. | 12 | $440 |
| Apellis Pharmaceuticals, Inc. | 7 | $392 |
| Eyepoint US, Inc. | 11 | $282 |
| Astellas Pharma US Inc | 13 | $266 |
| Novartis | 3 | $213 |
| Dutch Ophthalmic, USA | 2 | $196 |
| Bausch & Lomb Americas Inc. | 2 | $152 |
| Regeneron | 2 | $138 |
| Genentech, Inc. | 1 | $102 |
| ANI Pharmaceuticals, Inc. | 4 | $80 |
| Mallinckrodt Hospital Products Inc. | 3 | $77 |
| Amgen(2 entities) | 2 | $49 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Harrow Eye, LLC | 2 | $39 |
| Boston Scientific | 1 | $33 |
| Vyera Pharmaceuticals, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$7,200
- OZURDEX$4,313
- P200DTx$3,000
- EYLEA$336
- SUSVIMO$238
- VABYSMO$224
- XIPERE$127
- EVA, combined machine$105
- TISSUEBLUE$105
How this compares
$18,020 in reported general payments places this provider in the 80th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 96 | $2,257 |
| Prednisolone Acetate | 33 | $840 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $208 |
| Brimonidine Tartrate | 13 | $146 |
| Latanoprost | 14 | $128 |
| Ofloxacin | 13 | $97 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Irvine
- Baruch KuppermannIrvine$1M
- Mitul MehtaIrvine$192K
- Andrew BrowneIrvine$82K
- Kapil MishraIrvine$15K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Carlos Medina MendezSacramento$548K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.